Status:
COMPLETED
A Study of LY3484356 in Healthy Female Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy
Eligibility:
FEMALE
18-65 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to evaluate the amount of LY3484356 that is found in the blood stream and how long the body takes to get rid of it when given with and without food. Participants are ...
Eligibility Criteria
Inclusion
- Participants who are overtly healthy as determined by medical assessment
- Body mass index (BMI) within the range 18.0 to 35.0 kilograms per meter squared (kg/m²)
- Female participants of non childbearing potential. This includes females who are not pregnant, non-lactating and either: Infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy or bilateral salpingectomy, bilateral tubal ligation, or bilateral tubal occlusion), or alternate medical cause/congenital anomaly (for example, Müllerian agenesis) or postmenopausal
Exclusion
- Have a history or presence of cardiovascular (eg, symptomatic bradycardia with resting heart rate of \<60 beats per minute), respiratory, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs
- Show evidence of hepatitis B, evidence of hepatitis C and/or have evidence of human immunodeficiency virus (HIV) infection
- Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to dosing
- Use or intend to use medications that inhibit or induce CYP3A4 within 14 days prior to dosing until completion of the follow-up visit
- Smoke more than 10 cigarettes or use the equivalent tobacco, smoking-cessation products, nicotine-containing products, or e cigarettes (nicotine and non nicotine) per day
Key Trial Info
Start Date :
April 26 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 12 2022
Estimated Enrollment :
82 Patients enrolled
Trial Details
Trial ID
NCT04840888
Start Date
April 26 2021
End Date
April 12 2022
Last Update
December 11 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
LabCorp CRU, Inc.
Daytona Beach, Florida, United States, 32117
2
Covance Dallas
Dallas, Texas, United States, 75247